The offering provides near-term cash but at significant dilution for a $4M market cap company. Monitor the proxy filing timeline and stockholder vote outcome; failure to obtain approval could trigger price-protection provisions. The stock may face continued pressure given the capital raise and going-concern risks highlighted in forward-looking statements.
Price Chart
Executive Summary
iSpecimen priced a ~$2.5M private placement, issuing 488,281 shares at $5.12/share with pre-funded warrants, for working capital and marketing. The offering is capped at 19.99% of outstanding shares pending stockholder approval, and the company must file a proxy statement within 30 days of closing. This dilutive capital raise signals ongoing cash needs for a micro-cap with a $4M market cap.
Key Financial Metrics
Key Facts
- Private placement priced at $5.12/share for ~$2.5M gross proceeds.
- 488,281 shares issued; pre-funded warrants available to avoid >4.99% ownership.
- Offering capped at 19.99% of outstanding shares pending stockholder approval.
- Proceeds used for working capital, including up to $900K in marketing expenses.
- Expected closing on or about May 11, 2026.
- Company must file preliminary proxy within 30 days and hold stockholder meeting within 90 days post-closing.
- E.F. Hutton & Co. acting as exclusive placement agent.
Financial Impact
~$2.5M gross proceeds, representing ~12.2% dilution based on 488,281 shares vs. ~4M market cap (assuming ~4M shares outstanding pre-offering).
Risk Factors
- Substantial dilution to existing shareholders from the offering and potential anti-dilution adjustments.
- Risk of delisting if Nasdaq continued listing standards are not maintained.
- Going-concern uncertainty; company may need additional capital beyond this offering.
- Stockholder approval required for full share issuance; failure could limit future capital access.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | 8-K | $1.47 | awaiting T+60 | — | $0.8400 (+42.86%) |
Sep 4, 2026 7w ago | 8-K | $1.59 | awaiting T+60 | — | $0.8400 (−47.17%) |
Aug 14, 2026 10w ago | 8-K | $2.15 | awaiting T+60 | — | $0.8400 (+60.93%) |
Aug 7, 2026 11w ago | 8-K | $2.24 | awaiting T+60 | — | $0.8400 (+62.50%) |
Aug 7, 2026 11w ago | 424B4 | $2.22 | awaiting T+60 | — | $0.8400 (+62.16%) |
Jul 31, 2026 12w ago | EFFECT | $1.89 $0.8398 | ▲ +55.57% | ▲ +58.02% | $0.8400 (+55.56%) |
Jul 16, 2026 14w ago | S-1/A | $2.10 $1.08 | ▲ +48.57% | ▲ +53.25% | $0.8400 (+60.00%) |
Jul 14, 2026 14w ago | 8-K | $2.23 $1.09 | ▼ −51.12% | ▼ −53.65% | $0.8400 (−62.33%) |
Jun 18, 2026 18w ago | EFFECT | $2.59 $1.47 | ▲ +43.24% | ▲ +45.14% | $0.8400 (+67.57%) |
Jun 1, 2026 21w ago | 8-K | $3.07 $1.64 | ▲ +46.58% | ▲ +47.70% | $0.8400 (+72.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers